The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2024 | Updates in immunotherapy for lung cancer at WCLC 2024
Brian Henick, MD, Herbert Irving Comprehensive Cancer Center, New York, NY, comments on recent developments in immunotherapies fur lung cancer such as bispecific antibodies, and how to best utilize PD-1 inhibitors with them. Dr Henick additionally comments on VEGF, TIGIT and CTLA-4 inhibitors, as well as the need to elucidate biomarkers of response for antibody-drug conjugates. This interview took place at the 2024 World Conference on Lung Cancer (WCLC) in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
